Ergomed and PSR have joined forces to create a leading orphan drug development team that allows our clients to implement patient-driven solutions in their clinical trials. Clinical trials in rare diseases are not just smaller versions of large (conventional) trials and have specific requirements. We have been very privileged to work with many biotech and pharma pioneers over the last 18 years, assisting them with making new therapies available for rare disease patients. Both PSR's input to delivering new treatments and our participation in fundraising activities exemplify our dedication and passion toward the rare disease field, in business as well as the societal level. We are proud to be experts in the regulatory and clinical development of orphan drugs, working closely with patients, companies, patient groups, regulators, key opinion leaders, government funders and other stakeholders. WE CARE ABOUT RARE!